F. Hoffmann-La Roche Ltd.
95 announcements.
95 announcements.
Time | Date | Ticker | Company | Announcement |
---|---|---|---|---|
06:00 | 28-09-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche presents new 2-year data for Evrysdi (risdiplam) in infants with Type 1 spinal muscular atrophy (SMA) |
06:00 | 18-09-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche’s phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia |
06:03 | 18-09-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche launches new quantitative antibody test to measure SARS-CoV-2 antibodies, to support the evaluation of vaccines |
06:00 | 17-09-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020 |
06:00 | 16-09-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche receives FDA approval for expanded use of the CINtec PLUS Cytology test to aid clinicians in preventing cervical cancer |
06:00 | 11-09-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | New data further reinforce Roche’s OCREVUS (ocrelizumab) as a highly effective treatment for people with multiple sclerosis |
06:00 | 10-09-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | New data show Roche’s ENSPRYNG (satralizumab) significantly reduces severity and risk of relapse in neuromyelitis optica spectrum disorder (NMOSD) |
06:00 | 09-09-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche expands its multiple sclerosis portfolio with investigational BTK inhibitor fenebrutinib and initiates novel clinical trials for OCREVUS (ocrelizumab) |
06:00 | 08-09-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche receives FDA clearance for BK virus quantitative test on cobas 6800/8800 Systems to support better care for transplant patients |
06:00 | 07-09-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche announces FDA approval of Gavreto (pralsetinib) for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer |
06:00 | 04-09-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche receives FDA Emergency Use Authorization for the cobas SARS-CoV-2 & Influenza A/B Test for use on the cobas 6800/8800 Systems |
06:00 | 03-09-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche to present new data in multiple sclerosis and neuromyelitis optica spectrum disorder at MSVirtual2020 |
06:00 | 01-09-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche receives FDA approval for first HIV-1/HIV-2 Qualitative Test on the cobas 6800/8800 Systems in the fight against HIV/AIDS |
06:00 | 28-08-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche announces FDA approval of FoundationOne Liquid CDx, a comprehensive pan-tumour liquid biopsy test |
06:00 | 19-08-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche and Regeneron collaborate to significantly increase global supply of REGN-COV2 investigational antibody combination for COVID-19 |
06:00 | 17-08-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | FDA Approves Roche’s ENSPRYNG for Neuromyelitis Optica Spectrum Disorder (NMOSD) |
06:00 | 10-08-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche provides update on phase III studies of etrolizumab in people with moderately to severely active ulcerative colitis |
06:03 | 10-08-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | FDA approves Roche’s Evrysdi (risdiplam) for treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older |
06:00 | 05-08-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche announces FDA authorisation for the first Epstein-Barr virus quantitative test on the cobas 6800/8800 Systems to improve care for transplant patients |
06:00 | 03-08-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | Rozlytrek, Roche’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer |
06:00 | 31-07-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | FDA approves Roche’s Tecentriq plus Cotellic and Zelboraf for people with advanced melanoma |
06:00 | 29-07-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche provides an update on the phase III COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia |
06:00 | 23-07-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | First half of the year with 1%1 growth at constant exchange rates, significant impact of COVID-19 pandemic |
06:00 | 14-07-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche collaborates with Blueprint Medicines to bring a new treatment to people with RET-altered cancers |
06:00 | 13-07-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer |
06:03 | 13-07-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | New data from phase IIIb study reinforces safety profile of Roche’s Hemlibra in people with haemophilia A |
06:00 | 26-06-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche improves speed and accuracy of non-small cell lung cancer diagnosis with launch of automated digital pathology algorithm |
06:00 | 19-06-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche’s IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone met one of its co-primary endpoints |
06:00 | 18-06-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche’s Tecentriq in combination with chemotherapy (including Abraxane) meets primary endpoint of improved pathological complete response, regardless of PD-L1 status, as initial treatment for people with early triple-negative breast cancer |
06:00 | 04-06-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche’s Elecsys IL-6 test receives FDA Emergency Use Authorisation to help in identifying patients at high risk of severe inflammatory response |
06:00 | 02-06-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | FDA approves Roche’s Tecentriq in combination with Avastin for people with the most common form of liver cancer |
06:00 | 29-05-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | Updated data demonstrate Roche’s Alecensa increases overall survival rate for people with ALK-positive non-small cell lung cancer |
06:03 | 28-05-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche’s OCREVUS (ocrelizumab) shorter 2-hour infusion time approved in Europe |
06:00 | 28-05-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patients with severe COVID-19 pneumonia |
06:00 | 27-05-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche’s Port Delivery System with ranibizumab shows positive phase III results in neovascular age-related macular degeneration |
06:03 | 22-05-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche acquires Stratos Genomics to further develop DNA based sequencing for diagnostic use |
06:00 | 22-05-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | New longer-term data reinforce safety of Roche’s satralizumab in adults and adolescents with neuromyelitis optica spectrum disorder |
06:00 | 19-05-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | FDA approves Roche’s Tecentriq as a first-line monotherapy for certain people with metastatic non-small cell lung cancer |
06:00 | 15-05-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche launches new blood gas digital solution designed to improve patient care |
06:00 | 14-05-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche to present first clinical data on novel anti-TIGIT cancer immunotherapy tiragolumab at ASCO |
06:00 | 11-05-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | Changes to the Roche Enlarged Corporate Executive Committee |
06:00 | 07-05-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | New data at the ASCO20 Virtual Scientific Program reflects Roche’s commitment to accelerating progress in cancer care |
06:03 | 28-04-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | New 6-year data for Roche’s OCREVUS (ocrelizumab) show earlier treatment initiation nearly halves risk of needing walking aid in relapsing multiple sclerosis |
06:00 | 28-04-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche’s risdiplam shows significant improvement in survival and motor milestones in infants with Type 1 spinal muscular atrophy (SMA) |
06:00 | 22-04-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | First quarter with 2% growth in Swiss francs, 7%[1] at constant exchange rates |
06:00 | 21-04-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche receives FDA approval for cobas HPV test for use on the cobas 6800/8800 Systems to identify women at risk for cervical cancer |
06:00 | 20-04-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | US FDA and EMA accept applications for Roche’s OCREVUS (ocrelizumab) shorter 2-hour infusion time |
06:00 | 17-04-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche develops new serology test to detect COVID-19 antibodies |
06:00 | 11-03-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche receives FDA approval for CINtec PLUS Cytology test to aid clinicians in improving cervical cancer prevention |
06:00 | 04-03-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | FDA grants Breakthrough Device Designation for Roche's Elecsys GALAD score to support earlier diagnosis of hepatocellular carcinoma |
06:00 | 25-02-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | FDA accepts Roche’s Biologics License Application for fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast cancer |
06:00 | 19-02-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | FDA grants priority review to Roche’s Tecentriq monotherapy as first-line treatment of certain people with advanced non-small cell lung cancer |
06:00 | 14-02-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | China National Medical Products Administration grants approval of Roches Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer |
06:00 | 10-02-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche provides topline results from investigator-led Phase II/III trial with gantenerumab in rare inherited form of Alzheimers disease |
06:00 | 30-01-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche reports very strong results in 2019 |
06:00 | 27-01-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of liver cancer |
06:00 | 24-01-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche provides an update on Phase III study of Tecentriq in people with muscle-invasive urothelial cancer |
06:00 | 23-01-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roches Risdiplam meets primary endpoint in pivotal FIREFISH trial in infants with type 1 spinal muscular atrophy |
06:00 | 21-01-2020 | 0QQ6 | F. Hoffmann-La Roche Ltd | European Commission approves Roches Polivy for people with previously treated aggressive lymphoma |
06:00 | 23-12-2019 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche enters licensing agreement with Sarepta Therapeutics to improve the lives of patients living with Duchenne muscular dystrophy |
06:00 | 19-12-2019 | 0QQ6 | F. Hoffmann-La Roche Ltd | European Commission approves Roches Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment |
06:00 | 17-12-2019 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche purchases shares in tender offer for Spark Therapeutics, Inc. |
07:23 | 16-12-2019 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche and Spark Therapeutics, Inc. announce unconditional clearance by UK Competition and Markets Authority |
06:00 | 13-12-2019 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche announces positive Phase III study results for Tecentriq plus Cotellic and Zelboraf in people with previously untreated BRAF V600 mutation-positive advanced melanoma |
06:00 | 12-12-2019 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roches fixed-dose subcutaneous combination of Perjeta and Herceptin comparable to intravenous formulations in people with HER2-positive breast cancer |
06:00 | 10-12-2019 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche receives CE Mark for its Accu-Chek SugarView app |
06:03 | 09-12-2019 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. to December 16, 2019 |
06:00 | 09-12-2019 | 0QQ6 | F. Hoffmann-La Roche Ltd | Changes in the Board of Directors and the Corporate Executive Committee of Roche |
06:00 | 04-12-2019 | 0QQ6 | F. Hoffmann-La Roche Ltd | FDA approves Roches Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer |
06:00 | 02-12-2019 | 0QQ6 | F. Hoffmann-La Roche Ltd | Positive phase III results for Roches satralizumab in neuromyelitis optica spectrum disorder published in the New England Journal of Medicine |
06:00 | 25-11-2019 | 0QQ6 | F. Hoffmann-La Roche Ltd | FDA grants priority review to Roches risdiplam for spinal muscular atrophy |
06:00 | 22-11-2019 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. |
06:00 | 18-11-2019 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche to present new and updated data for seven approved and investigational medicines across multiple types of breast cancer at the 2019 San Antonio Breast Cancer Symposium |
06:00 | 11-11-2019 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roches risdiplam meets primary endpoint in pivotal SUNFISH trial in people with type 2 or 3 spinal muscular atrophy |
06:03 | 11-11-2019 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roches Gazyva (obinutuzumab), in combination with standard of care, more than doubles the percentage of lupus nephritis patients achieving complete renal response, compared to standard of care alone |
06:00 | 30-10-2019 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roches marketing applications for satralizumab in neuromyelitis optica spectrum disorder accepted for review by EMA and FDA |
06:00 | 29-10-2019 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. |
06:00 | 21-10-2019 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roches Tecentriq in combination with Avastin increased overall survival and progression-free survival in people with unresectable hepatocellular carcinoma |
06:00 | 18-10-2019 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche announces FDA approval of Xofluza (baloxavir marboxil) for people at high risk of developing influenza-related complications |
06:00 | 16-10-2019 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche reports very strong sales growth in the first nine months of 2019 outlook raised |
06:00 | 14-10-2019 | 0QQ6 | F. Hoffmann-La Roche Ltd | Phase III PEMPHIX study shows Roches MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris |
06:00 | 23-09-2019 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche to present new data from its broad oncology portfolio at the European Society for Medical Oncology 2019 Congress |
06:00 | 20-09-2019 | 0QQ6 | F. Hoffmann-La Roche Ltd | FDA approves cobas Babesia, Roches first whole blood test for donor screening |
06:00 | 19-09-2019 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche renews its commitment to the primary healthcare Phelophepa trains, marking the 25th anniversary |
06:00 | 18-09-2019 | 0QQ6 | F. Hoffmann-La Roche Ltd | FDA grants Breakthrough Therapy Designation for Roches Gazyva (obinutuzumab) in Lupus Nephritis |
06:00 | 16-09-2019 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche receives FDA clearance for cobas pro integrated solutions designed to help labs deliver faster results to patients |
08:00 | 16-09-2019 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche ranked as one of the most sustainable healthcare companies in the Dow Jones Sustainability Indices for the eleventh year running |
06:00 | 13-09-2019 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roches fixed-dose subcutaneous combination of Perjeta and Herceptin showed non-inferiority when compared to intravenous formulations for people with HER2-positive breast cancer |
06:03 | 13-09-2019 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche presents new 6-year OCREVUS (ocrelizumab) data which showed that earlier initiation and continuation of treatment reduced disability progression in multiple sclerosis |
06:00 | 12-09-2019 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roches Tecentriq as a first-line monotherapy helped certain people with advanced non-small cell lung cancer live longer compared with chemotherapy |
06:03 | 12-09-2019 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roches satralizumab significantly reduced relapse risk in second positive phase III study for neuromyelitis optica spectrum |
06:00 | 10-09-2019 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche presents new OCREVUS (ocrelizumab) biomarker data that increase understanding of disease progression in multiple sclerosis at ECTRIMS |
06:00 | 06-09-2019 | 0QQ6 | F. Hoffmann-La Roche Ltd | European Commission approves Roches new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer |
06:03 | 06-09-2019 | 0QQ6 | F. Hoffmann-La Roche Ltd | European Commission approves Roches Tecentriq in combination with chemotherapy for the initial treatment of people with extensive-stage small cell lung cancer |
06:00 | 04-09-2019 | 0QQ6 | F. Hoffmann-La Roche Ltd | Roche to present pivotal data for satralizumab in neuromyelitis optica spectrum disorder and six-year OCREVUS data in multiple sclerosis at ECTRIMS |